Gosset Year Founded
2002
Ownership
Public
Employees
~100
Stage
Phase 1
Modalities
Catalyst Biosciences General Information
Company has transitioned from Catalyst Biosciences to Gyre Therapeutics, focusing on fibrotic diseases with hydronidone (F351). Previously developed complement and coagulation system therapies which have been sold to other companies.
Contact Information
Drug Pipeline
hydronidone
Phase 1Key Partnerships
Biogen, GNI Group, GC Biopharma
Catalyst Biosciences Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Later Stage VC | Jan 27, 2021 | $50.0M | Completed | Phase 1 |
To view Catalyst Biosciences's complete valuation and funding history, request access »